620 F.Supp.3d 167
D.N.J.2022Background
- BD acquired CareFusion (2015) and inherited the Alaris infusion pump line, a core revenue driver for BD Medical that has a history of software-related safety problems and recalls (including a 2016 recall for low-battery alarm failures).
- BD attempted remediation via a 2017 510(k) submission (Project Monterey) but withdrew it in 2018 after FDA feedback identified documentation and software-change deficiencies; FDA issued a Form 483 in Sept. 2018 noting unresolved problems.
- In Fall 2019 BD met with FDA officials who, according to confidential witnesses, expressed that Alaris ‘‘should not be shipped’’ and that a 510(k) was needed; BD announced an Alaris ship hold on Nov. 5, 2019.
- BD briefly resumed shipments in Dec. 2019 after implementing software changes (without pre-notifying FDA); a subsequent call with FDA in late Dec./Jan. 2020 allegedly prompted BD to reinstate the ship hold and to prepare a consolidated 510(k).
- BD made public statements from Nov. 2019–Jan. 2020 characterizing the interruptions as software "upgrades" and forecasting FY20 growth; on Feb. 6, 2020 BD disclosed FDA required 510(k) clearance and halted Alaris sales, triggering a ~12% stock drop.
- Procedural posture: Plaintiff Industriens Pensionsforsikring repleaded the TAC after an earlier dismissal; court grants in part and denies in part Defendants’ motion to dismiss — claims against BD and Polen proceed; claims against Forlenza and Reidy are dismissed; claims based on the Feb. 4 recall notices are dismissed.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Material misstatements/omissions about the ship hold and FDA role | BD concealed that FDA effectively demanded a ship hold and a new 510(k); public statements ("upgrades", timing) were misleading | BD disclosed it was "in discussions" with FDA and had no duty to confess unadjudicated regulatory concerns; regulator action was speculative | Court: Plaintiff plausibly alleged materially misleading statements about the ship hold and FDA's role for many Class Period statements (but not the Feb. 4 recall notices) |
| Scienter of individual defendants | Officers (esp. Polen) knew the FDA’s position and acted recklessly/knowingly when making reassuring statements | Defendants lacked individualized allegations showing Forlenza/Reidy knew the undisclosed facts; stock sales don’t show motive | Court: Strong inference of scienter adequately pleaded as to Polen and BD; not adequately pleaded as to Forlenza, Reidy, or Gallagher — claims against those individuals dismissed |
| Safe-harbor / forward-looking guidance & reasonableness of FY20 projections | FY20 guidance and related statements lacked a reasonable basis because they depended on sustained Alaris sales while BD concealed FDA’s position | Forward-looking disclaimers/cautionary language and regulatory history immunize statements under PSLRA safe harbor | Court: Mixed present/future statements not protected for their present factual parts; cautionary language was not ‘‘meaningful’’ where risks had already materialized; projections plausibly lacked reasonable basis |
| Actionability of Feb. 4, 2020 voluntary recall notices | Recall notices omitted that FDA had rejected BD’s resumption of sales and required 510(k), making them misleading | Recall notices were not false or materially misleading because they did not address continued sales or regulatory prohibition | Court: Feb. 4 Recall Notices are not plausibly alleged to be materially false or misleading and claims based on them are dismissed |
| Loss causation | Feb. 6 disclosure revealed the concealed FDA position and precipitated the stock-price decline; links misstatements to investor losses | Disclosure did not reveal a hidden truth sufficient to establish causation | Court: Plaintiff pleaded loss causation adequately—Feb. 6 disclosure linked the prior misrepresentations to the stock drop |
Key Cases Cited
- Bell Atlantic Corp. v. Twombly, 550 U.S. 544 (2007) (establishes plausibility standard for Rule 12(b)(6))
- Ashcroft v. Iqbal, 556 U.S. 662 (2009) (applies and explains Twombly plausibility framework)
- Tellabs, Inc. v. Makor Issues & Rts., Ltd., 551 U.S. 308 (2007) (PSLRA scienter standard: inference of scienter must be at least as compelling as nonculpable inference)
- Dura Pharmaceuticals, Inc. v. Broudo, 544 U.S. 336 (2005) (loss causation requirement in securities fraud)
- Basic Inc. v. Levinson, 485 U.S. 224 (1988) (materiality and ‘‘total mix’’ principles for disclosure obligations)
- Matrixx Initiatives, Inc. v. Siracusano, 563 U.S. 27 (2011) (materiality standard for omitted adverse information)
- Omnicare, Inc. v. Laborers Dist. Council Constr. Ind. Pension Fund, 575 U.S. 175 (2015) (truthfulness requirement for public statements considered in context)
- Institutional Investors Group v. Avaya, Inc., 564 F.3d 242 (3d Cir. 2009) (confidential-witness pleading considerations and fraud pleading particularity)
- Williams v. Globus Medical, Inc., 869 F.3d 235 (3d Cir. 2017) (duty to avoid misleading partial disclosures about regulatory matters)